Clearside Biomedical, Inc. (CLSD)
- Previous Close
0.7399 - Open
0.7700 - Bid 0.7401 x 300
- Ask --
- Day's Range
0.7416 - 0.7768 - 52 Week Range
0.7000 - 1.6500 - Volume
208,571 - Avg. Volume
174,971 - Market Cap (intraday)
58.281M - Beta (5Y Monthly) 2.06
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4100 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.43
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
clearsidebio.comRecent News: CLSD
View More
Performance Overview: CLSD
Trailing total returns as of 6/3/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLSD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLSD
View MoreValuation Measures
Market Cap
57.50M
Enterprise Value
44.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.86
Price/Book (mrq)
--
Enterprise Value/Revenue
11.82
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-54.08%
Return on Equity (ttm)
--
Revenue (ttm)
3.76M
Net Income Avi to Common (ttm)
-30.81M
Diluted EPS (ttm)
-0.4100
Balance Sheet and Cash Flow
Total Cash (mrq)
13.63M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-21.45M
Research Analysis: CLSD
View MoreResearch Reports: CLSD
View MoreDaily – Vickers Top Buyers & Sellers for 04/22/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 02/12/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/08/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.